Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Haemonetics (HAE) Other Non Operating Income (2016 - 2025)

Historic Other Non Operating Income for Haemonetics (HAE) over the last 17 years, with Q4 2025 value amounting to -$7.4 million.

  • Haemonetics' Other Non Operating Income rose 1855.79% to -$7.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$23.9 million, marking a year-over-year decrease of 5263.12%. This contributed to the annual value of -$9.7 million for FY2025, which is 2513.44% up from last year.
  • As of Q4 2025, Haemonetics' Other Non Operating Income stood at -$7.4 million, which was up 1855.79% from -$7.2 million recorded in Q3 2025.
  • Haemonetics' Other Non Operating Income's 5-year high stood at $7.0 million during Q2 2024, with a 5-year trough of -$9.1 million in Q4 2024.
  • For the 5-year period, Haemonetics' Other Non Operating Income averaged around -$4.2 million, with its median value being -$4.5 million (2021).
  • The largest annual percentage gain for Haemonetics' Other Non Operating Income in the last 5 years was 43624.94% (2024), contrasted with its biggest fall of 36752.18% (2024).
  • Over the past 5 years, Haemonetics' Other Non Operating Income (Quarter) stood at -$4.6 million in 2021, then skyrocketed by 77.01% to -$1.1 million in 2022, then crashed by 84.74% to -$1.9 million in 2023, then crashed by 367.52% to -$9.1 million in 2024, then increased by 18.56% to -$7.4 million in 2025.
  • Its last three reported values are -$7.4 million in Q4 2025, -$7.2 million for Q3 2025, and -$8.7 million during Q2 2025.